Rapid Dose Announces Payment in Shares for Quarterly Interest on Secured Debt
Rhea-AI Summary
Rapid Dose Therapeutics (CSE: DOSE) announced plans to issue common shares to satisfy the quarterly interest payment due December 31, 2024, on its secured convertible notes. The company will issue 430,930 common shares at $0.22 per share to cover $94,806.23 in accrued interest.
This share issuance stems from the company's previous private placement financing, where RDT issued $3,134,445 in principal amount of Notes and 15,672,225 Warrants in 2023. The Notes, maturing on November 30, 2025, carry a 12.0% annual interest rate, payable quarterly in common shares. The share price is determined by the closing market price on the CSE at each quarter's end.
The newly issued shares will be subject to a four-month and one-day hold period from their issue date, expected no later than January 15, 2025.
Positive
- None.
Negative
- Company continues to pay interest through share issuance, indicating potential cash flow constraints
- Additional share issuance of 430,930 shares creates dilution for existing shareholders
- High interest rate of 12% annually on convertible notes indicates expensive debt financing
News Market Reaction – RDTCF
In the trading session that priced this news, RDTCF declined 22.61%, reflecting a significant negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Burlington, Ontario--(Newsfile Corp. - January 7, 2025) - Rapid Dose Therapeutics Corp. (CSE: DOSE) ("RDT" or the "Company") announced today that as contemplated in the secured convertible notes (the "Notes") previously issued on its private placement financing (the "Financing"), and consistent with prior quarters, the Company intends to issue common shares ("Common Shares") in satisfaction of the accrued interest payable on December 31, 2024 under the terms of the Notes. The Company expects to issue the Common Shares no later than January 15, 2025.
The Financing was an offering of units (the "Units") at a price of
The Notes have a maturity date of November 30, 2025 and bear interest from their date of issue at
Therefore, in accordance with the terms of the Notes, the Company intends to issue 430,930 Common Shares to the holders of the Notes at a deemed issue price of
All Common Shares issued as payment for accrued interest will be subject to a hold period expiring four months and one day from the date of issue of the Common Shares.
About Rapid Dose Therapeutics Corp.
Rapid Dose Therapeutics is a Canadian biotechnology company revolutionizing drug delivery through innovation. The Company's flagship product QuickStrip™ is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients, including nutraceuticals, pharmaceuticals and vaccines, that are delivered quickly into the bloodstream, resulting in rapid onset of the active ingredient. For more information about the Company, visit www.rapid-dose.com.
Contacts:
RDT Investor Contact:
Mark Upsdell, CEO
investorrelations@rapid-dose.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
Certain information in this news release may contain forward-looking information within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as "intend", "may", "should", "anticipate", "expect", "potential", "believe", "intend", "will", "could", "are planned to", "are expected to" or the negative of these terms and similar expressions. Statements containing forward-looking information, including, without limitation, in respect of the delivery of equipment and products using the QuickStrip™ product delivery method, the generation of recurring revenues, the plans, estimates, forecasts, projections, expectations or beliefs of RDT management as to future events or results and are believed to be reasonable based on information currently available to RDT management. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; termination of WLM agreements; future legislative and regulatory developments involving cannabis; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability to implement its business strategies; competition; currency and interest rate fluctuations and other risks. Readers are cautioned that the foregoing list is not exhaustive. There can be no assurance that statements of forward-looking information, although considered reasonable by RDT management at the time of preparation, will prove to be accurate as there can be no assurance that the plans, intentions or expectations upon which they are based will occur. Actual results and future events could differ materially from those anticipated in such forward-looking statements. Readers should not place undue reliance on forward-looking statements. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/236350